XNAS
IDXX
Market cap40bUSD
Oct 08, Last price
513.14USD
1D
1.28%
1Q
-8.95%
Jan 2017
337.57%
Name
IDEXX Laboratories Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
IDEXX Laboratories, Inc. is a global enterprise dedicated to creating, producing, and distributing a broad spectrum of products and services. Its primary focus lies in serving the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company delivers crucial solutions across several key areas. For companion animals, IDEXX offers comprehensive veterinary diagnostic tools, including in-clinic point-of-care instruments, consumables, and rapid assay test kits. They also provide expert veterinary reference laboratory diagnostics, consulting services, and advanced practice management and diagnostic imaging systems. Beyond pets, their portfolio extends to health monitoring and diagnostic products vital for livestock, poultry, and dairy farming. In the water quality segment, IDEXX manufactures tests designed to detect various microbiological contaminants, ensuring safety and compliance, with notable examples like the Colilert, Enterolert, and Legiolert tests. IDEXX also serves the biomedical research community with health monitoring and laboratory animal diagnostic instruments and services. Furthermore, they contribute to human point-of-care medical diagnostics by providing specialized electrolytes and blood gas analyzers, alongside SARS-CoV-2 RT-PCR solutions. Their extensive product lineup features various in-clinic chemistry, blood, and urine analyzers (such as the SediVue Dx), hematology systems, and rapid diagnostic assays like SNAP test kits. Complementing these offerings, the company provides essential veterinary software solutions for both independent and corporate veterinary practices. Sales and distribution are managed through their dedicated marketing, customer service, sales, and technical support teams, supplemented by a network of independent distributors and other resellers. Established in 1983, IDEXX Laboratories, Inc. maintains its headquarters in Westbrook, Maine.
Related entities
Subsidiaries (5)
IDEXX B.V.
IDEXX LABORATORIES CANADA CORPORATION
IDEXX LABORATORIES PTY LIMITED
IDEXX Laboratories, KK
IDEXX EUROPE B.V.
Key people
Jonathan Mazelsky
Executive Chairman of the Board · since 2026
Andrew Emerson
Executive Vice President, Chief Executive Officer, Treasurer · since 2025
George Fennell
Executive Vice President - Global CAG Commercial · since 2025
Tina Hunt
Executive Vice President - Global Strategy and Commercial · since 2025
Michael Johnson
Chief Human Resources Officer, Executive Vice President · since 2024
Michael Lane
Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology · since 2025
Martin Smith
Executive Vice President - Global Operations and R&D · since 2025
Sharon Underberg
Executive Vice President, General Counsel, Corporate Secretary · since 2021
Michael Erickson
Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine · since 2024
Michael Schreck
Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer Experience · since 2024
Lead Independent Director · since 2026
Independent Director · since 2023
Independent Director · since 2015
Independent Director · since 2017
Independent Director · since 2025
Independent Director · since 2014
Independent Director · since 2025
Independent Director · since 2019
Sophie Vandebroek
Independent Director · since 2013
Headquarters & legal address
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
WILMINGTON, DE 19801
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||